Predictive features associated with chronic spontaneous urticaria recurrence

When chronic spontaneous urticaria (CSU) is resolved, patients are often apprehensive about the likelihood of recurrence, and want to know if we can predict this using clinical or laboratory markers. This question is crucial because CSU is frequently accompanied by a high incidence of stressful comorbidities, and the fear of experiencing this again can be devastating to the patient. This study was designed with the aim of focusing on the prevalence and characteristics of the recurrence of CSU. We used our CSU patient registry that includes data on 180 patients who are followed periodically. In 23 (13%) patients, CSU was resolved during the first year. In 47 (26%) patients, CSU lasted more than 5 years. The recurrence of CSU was recorded in 21% of our patients after having experienced a full remission anywhere between 1 to 10 years (mean ± 2.9 years). While investigating predictive clinical or laboratory markers, we noticed that bronchial asthma existed in 10/25 (40%) of patients in whom CSU recurred as compared with 45/180 (25%) in the general CSU population (p = 0.049). In addition, increased levels of total immunoglobulin (Ig)E were found in 10/25 (40%) of the recurrence group as compared with 34/150 (23%) of the general CSU group (p = 0.04). Anti‐thyroid peroxidase antibodies were also found in 11/25 (44%) of the recurrence group as compared with 32/160 (20%) of the general group (p = 0.003). The prevalence of CSU recurrence after a full remission is significantly higher among patients with existing bronchial asthma, increased levels of total IgE, and autoimmunity. Further studies are required in order to substantiate this important issue.

[1]  A. Giménez-Arnau,et al.  Definition of Recurrent Chronic Spontaneous Urticaria , 2020, Acta dermato-venereologica.

[2]  S. González-Díaz,et al.  Chronic urticaria and thyroid pathology , 2020, The World Allergy Organization journal.

[3]  C. Vestergaard,et al.  Risk of comorbidities in patients diagnosed with chronic urticaria: A nationwide registry-study , 2020, The World Allergy Organization journal.

[4]  T. Ergun,et al.  Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study , 2019, The Journal of dermatological treatment.

[5]  B. Sekerel,et al.  Children With Chronic Spontaneous Urticaria: Recurrence After Remission And Its Predictors. , 2020, The journal of allergy and clinical immunology. In practice.

[6]  S. Abraham,et al.  Autoimmune Theories of Chronic Spontaneous Urticaria , 2019, Front. Immunol..

[7]  D. Khan,et al.  Recurrence of Chronic Urticaria: Incidence and Associated Factors. , 2017, The journal of allergy and clinical immunology. In practice.

[8]  M. Maurer,et al.  Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  O. Schmetzer,et al.  Autoimmune chronic spontaneous urticaria: What we know and what we do not know , 2017, The Journal of allergy and clinical immunology.

[10]  M. Maurer,et al.  Potential blood biomarkers in chronic spontaneous urticaria , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  P. Hodgkin,et al.  Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor Iα subunit. , 2016, The Journal of allergy and clinical immunology.